Premium
Newer anesthetics end their uses
Author(s) -
Dobkin Allen B.,
PoGiok Su Jane
Publication year - 1966
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196675648
Subject(s) - mepivacaine , anesthetic , methoxyflurane , halothane , anesthesia , medicine , alfentanil , enflurane , anesthetic agent , adverse effect , nitrous oxide , prilocaine , analgesic , pharmacology , intensive care medicine , local anesthetic , propofol
Most anesthetics in general use ten years ago had important undesirable properties which limited the seope of their usefulness or were inherently dangerous in the seriously ill patient. New inhalation, intravenous, and loeal anestheties have been synthesized sinee then which more closely fill the needs of the clinical anesthesiologist and the patient. Halothane and methoxyflurane have obvious advantages over cyclopropane and diethyl ether because they are nonexplosive and cause less metabolic disturbance. We would welcome a new gaseous anesthetic more potent than nitrous oxide, less potent than cyclopropane, and completely free from adverse effects on the myocardium and the liver. Of the intravenous anesthetics, only methohexital appears to have even slight advantages over thiopental. We still need an intravenous anesthetic that is more rapidly detoxified or exereted, is a potent hypnotic and analgesic, and is free from adverse effects on the medulla and neuromuscular apparatus. The quest for less toxic and more potent or longer‐acting local anesthetic agents has resulted in the development of prilocaine and mepivacaine. Laboratory and clinical studies of both of these agents have failed to demonstrate any clear advantages over older ones.